Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: A meta-analysis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bosco, Cecilia ^a   Crawley, Danielle ^a,b   Adolfsson, Jan ^c   Rudman, Sarah ^b   Van Hemelrijck, Mieke ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ACUTE HEART INFARCTION; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY COMPOSITION; CASE CONTROL STUDY; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; ORCHIECTOMY; OSTEOPOROSIS; PREVALENCE; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT DURATION; COMPLICATION; MALE; META ANALYSIS; PROSTATIC NEOPLASMS; PUBLISHING;

ANDROGEN ANTAGONISTS; DIABETES MELLITUS; HUMANS; MALE; METABOLIC SYNDROME X; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK FACTORS;

EID: 84925845413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117344     Document Type: Article

References (44)

1. Huggins C, Stevens R, Hodge C (1941) Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209-223.
2. DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, et al. (2008) Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 102: 39-43. doi: 10.1111/j.1464-410X.2008.07505.x PMID: 18294309
3. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79: 933-941. PMID: 9202563
4. Sprenkle PC, Fisch H (2007) Pathologic effects of testosterone deprivation. Curr Opin Urol 17: 424-430. PMID: 17921778
5. Petrylak PJ, WM. (2002) Androgen Abliation for Prostate Cancer: Mechanisms and Modalities. In: Kantoff PC, D'Amico PR., AV., editor. Prostate Cancer: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins.
6. Keating NL, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456. PMID: 16983113
7. Hakimian P, Blute M Jr, Kashanian J, Chan S, Silver D, et al. (2008) Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int.
8. Nobes JP, Langley SE, Laing RW (2008) Metabolic Syndrome and Prostate Cancer: A Review. Clin Oncol (R Coll Radiol).
9. Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, et al. (2010) Risk of thromboembolic diseases in men with prostate cancer: Results from the population-based PCBaSe. Lancet Oncology 11: 450-458. doi: 10.1016/S1470-2045(10)70038-3 PMID: 20395174
10. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, et al. (2010) Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden. J Clin Oncol 28: 34778-34756.
11. Saylor PJ, Smith MR (2013) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 189: S34-42; discussion S43-34. doi: 10.1016/j.juro.2012.11.017 PMID: 23234628
12. Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115: 2388-2399. doi: 10.1002/cncr.24283 PMID: 19399748
13. Collier A, Ghosh S, McGlynn B, Hollins G (2012) Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol 35: 504-509. PMID: 21297430
14. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645. doi: 10.1161/CIRCULATIONAHA.109.192644 PMID: 19805654
15. Allott EH, Masko EM, Freedland SJ (2013) Obesity and prostate cancer: weighing the evidence. Eur Urol 63: 800-809. doi: 10.1016/j.eururo.2012.11.013 PMID: 23219374
16. Gruca D, Bacher P, Tunn U (2012) Safety and tolerability of intermittent androgen deprivation therapy: a literature review. Int J Urol 19: 614-625. doi: 10.1111/j.1442-2042.2012.03001.x PMID: 22435512
17. Smith MR (2008) Treatment-related diabetes and cardiovascular disease in prostate cancer survivors. Ann Oncol 19 Suppl 7: vii86-90. doi: 10.1093/annonc/mdn458 PMID: 18790986
18. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, et al. (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87: 599-603. PMID: 11836291
19. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, et al. (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261-4267. PMID: 11549659
20. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 4: 128-139. doi: 10.1007/s11764-009-0114-1 PMID: 20091248
21. STROBE, STrengthening the Reporting of OBservational studies in Epidemiology-Checklist 2014, 6 October, http://www.strobe-statement.org/index.php?id = available-checklists.
22. International Diabetes Federation (2006) The IDF consensus worldwide definition of the metabolic syndrome
23. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497. PMID: 11368702
24. Faris JE, Smith MR (2010) Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 17: 240-246. doi: 10.1097/MED.0b013e3283391fd1 PMID: 20404727
25. site UFaDAW, FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GNRH agonists to add new safety information to labelling regarding increased risk of diabetes and certain cardiovascular diseases, 2013, June 17, 2013, http://www.fda.gov/ Drugs/DrugSafety/ucm229986.htm.
26. Keating NL, O'Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102: 39-46. doi: 10.1093/jnci/djp404 PMID: 19996060
27. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, et al. (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27: 3452-3458. doi: 10.1200/ JCO.2008.20.0923 PMID: 19506162
28. Terrier JE, Mottet N (2013) [Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone]. Prog Urol 23: 88-95. doi: 10.1016/j.purol.2012.09.008 PMID: 23352300
29. Jones T (2007) Hypogonadism in men with type 2 diabetes. Practical Diabetes International 24: 269-277.
30. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M (2011) Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice & Research Clinical Endocrinology & Metabolism 25: 337-353.
31. Corona G, Mannucci E, Forti G, Maggi M (2009) Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. International journal of andrology 32: 587-598. doi: 10.1111/j.1365-2605.2008.00951.x PMID: 19226407
32. Corona G, Forti G, Maggi M (2008) Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. The Aging Male 11: 193-199. doi: 10.1080/13685530802468497 PMID: 19172551
33. Shahani S, Braga-Basaria M, Basaria S (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. The Journal of Clinical Endocrinology & Metabolism 93: 2042-2049.
34. Grundy SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. The Journal of Clinical Endocrinology & Metabolism 89: 2595-2600.
35. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science 104: 195. PMID: 12546642
36. Saad F, Aversa A, Isidori AM, Gooren LJ (2012) Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Current diabetes reviews 8: 131. PMID: 22268394
37. Keating NL, O'Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer. J Natl Cancer Inst 102: 39-46. doi: 10.1093/jnci/djp404 PMID: 19996060
38. Lage MJ, Barber BL, Markus RA (2007) Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70: 1104-1108. PMID: 18158027
39. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, et al. (2006) Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24: 3979-3983. PMID: 16921050
40. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106: 581-588. PMID: 16388523
41. Bo J, Zhang L, Liu P, Sha J, Lv J, et al. (2011) Androgen deprivation therapy through bilateral orchiectomy: Increased metabolic risks. Asian Journal of Andrology. pp. 883-837.
42. th Annual Meeting of the American Society fo Radiation Oncology, ASTRO 2013. Atlanta, GA. pp. 356.
43. Ropero Valverde J, Planas Morin J, Salvador Lacambra C, Trilla Herrera E, Placer Santos J, et al. (2011) Prevalence of metabolic syndrome in prostate cancer patients under androgen deprivation therapy: Interim results of a case-control study. European Urology Supplements 10: 337.
44. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, et al. (2009) Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes. J Clin Oncol 27: 3452-3458. doi: 10.1200/ JCO.2008.20.0923 PMID: 19506162